spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Osteocel 

 HSMN NewsFeed - 12 Jun 2018
NuVasive Launches AttraX Scaffold Biologic And Reports First Clinical Use
Devices Orthopaedic Neurosurgery Product Launch
 HSMN NewsFeed - 8 May 2008
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
Regenerative Medicine Acquisitions
 HSMN NewsFeed - 8 May 2008
Osiris and NuVasive Enter into Definitive Agreement for Osteocel(R)
Regenerative Medicine
 HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Regenerative Medicine FDA
 HSMN NewsFeed - 27 Feb 2008
Osiris Therapeutics Strengthens Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 7 Jan 2008
Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal(TM)
Regenerative Medicine Cardiology
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 27 Nov 2007
Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair
Regenerative Medicine Orthopaedic
 HSMN NewsFeed - 23 Nov 2007
Osiris Therapeutics Announces Management Change
Regenerative Medicine Personnel
 HSMN NewsFeed - 9 Oct 2007
Osiris Therapeutics Secures $30 Million Financing Commitment from Chairman and Largest Shareholder
Regenerative Medicine
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 19 Oct 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Oct 2006
Osiris is Granted European Manufacturing Certification for PROCHYMAL(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Oct 2006
Osiris Therapeutics Receives Approval from Health Canada to Conduct Phase III Clinical Trial for Lead Stem Cell Drug
Biopharmaceuticals Regenerative Medicine Regulatory
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Osteocel
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.